Harnessing Single-Cell Multi-Omic Energy States for Integrated Cancer Biology

Discover how scientists use multi-omic approaches to identify functional changes that lead to cancer cell drug resistance and devise new treatment strategies.

The Scientist Creative Services Team
Jan 20, 2021

FREE Webinar

Tuesday, February 16, 2021
11:30 AM - 1:00 PM, Eastern Standard Time

Register Now

The development of drug resistance is an almost universal characteristic of cancers, and is an outstanding challenge in the fields of tumor biology and clinical oncology. While there have been many studies focused on genomic contributions to resistance in cancer cells, recent studies have shown that genetically homogeneous cells can undergo adaptive cell state changes leading to the rapid emergence of drug-tolerant phenotypes. The heterogeneous nature of tumors, coupled with the functional and metabolic changes that accompany adaptive resistance development, suggests that  multi-omic, single cell approaches have the potential to provide deep insights into the cell state changes that lead to adaptive resistance, and may provide hypotheses for new therapies and therapy combinations that can prevent resistance development. IsoPlexis’ multi-omic (metabolomics + functional proteomics) energy state application provides a critical and uniquely capable tool for addressing this biology.

Through the use of IsoPlexis’ multi-omic energy state application, independent trajectories to drug tolerance can be revealed, enabling researchers to better develop combination therapies to combat this drug-resistant cell state and prevent drug resistance.

Learn more about this groundbreaking innovative technology and its unique applications in this webinar.

Topics to be covered

  • Cellular, metabolic, and proteomic changes during drug treatment that lead to resistance
  • Using multi-omic approaches to reveal functional adaptations
  • Identifying and countering independent trajectories to drug tolerance

Register Now

James R. Heath, PhD
President and Professor
Institute for Systems Biology, Seattle


Sean Mackay
CEO and Co-Founder
IsoPlexis